HB 219 requires Ohio health insurers to maintain networks ensuring all plan members - especially low-income individuals, children, people with disabilities, and those with chronic conditions - can access needed care without unreasonable travel or delays. Insurers must provide sufficient providers by specialty (including those serving underserved communities), guarantee 24/7 emergency services, and meet specific geographic accessibility standards. The state insurance superintendent will set evaluation criteria (like provider-to-patient ratios and appointment wait times) and monitor compliance through surveys, with insurers required to file network plans for approval. This law directly affects health insurers operating in Ohio, mandating concrete network standards to improve access to care.
SB 162 amends Ohio's Revised Code section 3901.388 to change the timeframe health insurers must use when recouping overpayments from healthcare providers. This directly affects health insurers and the providers who bill them for services. The bill specifies a new deadline for insurers to request repayment after identifying overpayments, replacing the previous timeframe outlined in the existing law. The change focuses solely on the timing mechanism for recoupment, without altering the conditions under which recoupment occurs.
To enact sections 3902.65, 4765.362, and 5164.11 of the Revised Code to establish community paramedicine programs and to require insurance coverage for services provided under those programs.
To enact section 3902.55 of the Revised Code to prohibit health plan issuers from requiring or inducing providers to collect copayments and other cost sharing amounts.
HB 8 requires health insurance plans and Ohio Medicaid to cover biomarker testing for diagnosis, treatment, and ongoing disease monitoring when ordered by a provider as medically necessary. The bill mandates coverage only for tests supported by specific evidence, such as FDA-approved uses, clinical guidelines, or peer-reviewed studies showing improved health outcomes, and explicitly excludes screening purposes. It also requires plans to minimize disruptions in care (like multiple biopsies) and ensures an accessible appeal process for coverage denials. This affects patients with conditions requiring these tests and healthcare providers ordering them, but does not change existing coverage for screening.
To amend sections 1751.72, 3923.041, and 5160.34 of the Revised Code regarding health insurance and Medicaid program prior authorization requirements.
To enact section 3902.66 of the Revised Code to require health insurers to cover preventive screenings for certain men at high-risk for developing prostate cancer.
HB 388 requires state health plans to reimburse state employees and elected officials for costs associated with GLP-1 medications (used for conditions like diabetes or obesity). It adds these specific drugs to the list of covered expenses under existing reimbursement policies. The bill establishes a clear process for employees to seek reimbursement for these medications through their state health plan. This directly affects state workers who use GLP-1 drugs and ensures their costs are covered under state health benefits.
To amend sections 3901.382 and 5164.46 of the Revised Code to prohibit fees for electronic claims submission by health insurer and the Medicaid program.
To amend sections 3923.33, 3923.331, 3923.332, 3923.337, 3923.338, 3923.339, and 3923.42 and to enact section 3923.3310 of the Revised Code to provide Medigap policies for Medicare-eligible individuals under the age of 65.